Researchers reported engineering allogeneic mesenchymal stem cells (MSCs) with mRNA to enhance immunomodulatory properties and created a candidate called DC‑25 that aims to overcome limitations of autologous cell therapies. The study describes how transient mRNA delivery reprograms MSCs to increase immune engagement and persistence, positioning DC‑25 as a potential allogeneic off‑the‑shelf cell therapy for immunotherapy applications. The authors highlight translational advantages—standardized manufacture and reduced patient‑by‑patient variability—while noting standard safety and immunogenicity assessments remain necessary before clinical trials. For readers unfamiliar, allogeneic MSCs are donor‑derived stromal cells used to modulate immune responses; mRNA here is a non‑integrating means to transiently change cellular function.